The Biosecurity Threat Posed by Biological Toxins

  • Brenda A. Wilson
  • Mengfei Ho
Reference work entry
Part of the Toxinology book series (TOXI, volume 1)


Biological toxins are highly diverse and produced in nature by a wide variety of organisms. A number of key features favor the potential threat of these biotoxins as bioterror agents, including their high potency, the relatively long latency period before symptoms are manifested, the difficulty in detecting or diagnosing their presence and identity, and their relative ease in production and stability in the environment. All of these features also create major challenges in developing tools and reagents to combat toxin-mediated diseases. So far, there have been a limited number of toxins that have drawn attention for potential use as bioterror agents, but there are many more naturally occurring toxins that have been isolated, purified, and characterized, as well as cloned and modified to make different recombinant variants. Current treatments for toxin exposure are limited to vaccination or passive immunization with antibodies; however, there are no postexposure therapies available after symptoms have manifested. A vigilant and robust biotoxin research community must be mobilized to not only better characterize the existing biotoxins but also to anticipate new variants or entirely new biotoxins that might arise and to develop appropriate antitoxin countermeasures. In addition, a definitive roadmap must also be formulated for safe, documented, and controlled handling of biotoxins during basic research and during development of toxin-based therapeutics for biomedical applications.


Botulinum Neurotoxin Protein Toxin Wound Botulism Infant Botulism Biological Toxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abramson SN, Radic Z, Manker D, Faulkner DJ, Taylor P. Onchidal: a naturally occurring irreversible inhibitor of acetylcholinesterase with a novel mechanism of action. Mol Pharmacol. 1989;36(3):349–54.PubMedGoogle Scholar
  2. Aktories K, editor. Botulinum neurotoxins. Heidelberg: Springer; 2013.Google Scholar
  3. Alouf JE, Popoff MR, editors. The comprehensive sourcebook of bacterial protein toxins. 3rd ed. San Diego: Elsevier/Academic; 2006.Google Scholar
  4. Anderson PD. Bioterrorism: toxins as weapons. J Pharm Pract. 2012;25(2):121–9.CrossRefPubMedGoogle Scholar
  5. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059–70.CrossRefPubMedGoogle Scholar
  6. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462–71.CrossRefPubMedGoogle Scholar
  7. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis. 2014;209(2):183–91.Google Scholar
  8. Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev. 2003;16(3):497–516.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Bigalke H, Rummel A. Medical aspects of toxin weapons. Toxicology. 2005;214(3):210–20.CrossRefPubMedGoogle Scholar
  10. Binder P, Attre O, Boutin JP, Cavallo JD, Debord T, Jouan A, et al. Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Comp Immunol Microbiol Infect Dis. 2003;26(5–6):401–21.CrossRefPubMedGoogle Scholar
  11. Blunden G. Biologically active compounds from marine organisms. Phytother Res. 2001;15(2):89–94.CrossRefPubMedGoogle Scholar
  12. Calvete JJ, Sanz L, Angulo Y, Lomonte B, Gutierrez JM. Venoms, venomics, antivenomics. FEBS Lett. 2009;583(11):1736–43.CrossRefPubMedGoogle Scholar
  13. CDC. National Center for Emerging and Zoonotic Infectious Disease: national botulism surveillance summaries – 2001–2011. [Summary Report] 2011 [updated 06/25/2013; cited 08/08/2013]; (2011).
  14. Crenshaw M. Explaining terrorism: causes, processes and consequences (political violence). 1st ed. Wilkinson P, Rapoport D, editors. New York: Routledge/Taylor & Francis Group; 2011.Google Scholar
  15. Daly JW, Spande TF, Garraffo HM. Alkaloids from amphibian skin: a tabulation of over eight-hundred compounds. J Nat Prod. 2005;68(10):1556–75.CrossRefPubMedGoogle Scholar
  16. De Castro C, Holst O, Lanzetta R, Parrilli M, Molinaro A. Bacterial lipopolysaccharides in plant and mammalian innate immunity. Protein Pept Lett. 2012;19(10):1040–4.CrossRefPubMedGoogle Scholar
  17. Dittmann E, Fewer DP, Neilan BA. Cyanobacterial toxins: biosynthetic routes and evolutionary roots. FEMS Microbiol Rev. 2013;37(1):23–43.CrossRefPubMedGoogle Scholar
  18. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis. 2014;209(2):192–202.Google Scholar
  19. Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, et al. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J. 2012;279(14):2555–67.CrossRefPubMedGoogle Scholar
  20. Escoubas P. Molecular diversification in spider venoms: a web of combinatorial peptide libraries. Mol Divers. 2006;10(4):545–54.CrossRefPubMedGoogle Scholar
  21. Ganesan K, Raza SK, Vijayaraghavan R. Chemical warfare agents. J Pharm Bioallied Sci. 2010;2(3):166–78.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Hallen HE, Luo H, Scott-Craig JS, Walton JD. Gene family encoding the major toxins of lethal Amanita mushrooms. Proc Natl Acad Sci U S A. 2007;104(48):19097–101.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Henghold 2nd WB. Other biologic toxin bioweapons: ricin, staphylococcal enterotoxin B, and trichothecene mycotoxins. Dermatol Clin. 2004;22(3):257–62, v.CrossRefPubMedGoogle Scholar
  24. Hill SE, Iqbal R, Cadiz CL, Le J. Foodborne botulism treated with heptavalent botulism antitoxin. Ann Pharmacother. 2013;47(2):e12.CrossRefPubMedGoogle Scholar
  25. Ho M, Chang LH, Pires-Alves M, Thyagarajan B, Bloom JE, Gu Z, et al. Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Protein Eng Des Sel. 2011;24(3):247–53.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep. 2008;25(3):447–54.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Hu WG, Yin J, Chau D, Negrych LM, Cherwonogrodzky JW. Humanization and characterization of an anti-ricin neutralization monoclonal antibody. PLoS One. 2012;7(9):e45595.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Hwang DF, Noguchi T. Tetrodotoxin poisoning. Adv Food Nutr Res. 2007;52:141–236.CrossRefPubMedGoogle Scholar
  29. Joseph R, Pahari S, Hodgson WC, Kini RM. Hypotensive agents from snake venoms. Curr Drug Targets Cardiovasc Haematol Disord. 2004;4(4):437–59.CrossRefPubMedGoogle Scholar
  30. Katona P. Botulinum toxin: therapeutic agent to cosmetic enhancement to lethal biothreat. Anaerobe. 2012;18(2):240–3.CrossRefPubMedGoogle Scholar
  31. Kim IJ, Blanke SR. Remodeling the host environment: modulation of the gastric epithelium by the Helicobacter pylori vacuolating toxin (VacA). Front Cell Infect Microbiol. 2012;2:37.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Mackessy SP, editor. Handbook of venoms and toxins of reptiles. Boca Raton: Taylor & Francis Group/CRC Press; 2010.Google Scholar
  33. Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med. 2001;21(3):593–605.PubMedGoogle Scholar
  34. Makarovsky I, Markel G, Hoffman A, Schein O, Brosh-Nissimov T, Tashma Z, et al. Strychnine–a killer from the past. Isr Med Assoc J. 2008;10(2):142–5.PubMedGoogle Scholar
  35. McCleary RJ, Kini RM. Snake bites and hemostasis/thrombosis. Thromb Res. 2013;132:642–6.CrossRefPubMedGoogle Scholar
  36. Morens DM, Fauci AS. Emerging infectious diseases: threats to human health and global stability. PLoS Pathog. 2013;9(7):e1003467.CrossRefPubMedPubMedCentralGoogle Scholar
  37. Olivera BM, Teichert RW. Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery. Mol Interv. 2007;7(5):251–60.CrossRefPubMedGoogle Scholar
  38. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221–37.CrossRefPubMedGoogle Scholar
  39. Paterson RR. Fungi and fungal toxins as weapons. Mycol Res. 2006;110(Pt 9):1003–10.CrossRefPubMedGoogle Scholar
  40. Popoff MR. Botulinum neurotoxins: more and more diverse and fascinating toxic proteins. J Infect Dis. 2014;209(2):168–9.Google Scholar
  41. Relman DA. Inconvenient truths in the pursuit of scientific knowledge and public health. J Infect Dis. 2014;209(2):170–2.Google Scholar
  42. Salem H. Issues in chemical and biological terrorism. Int J Toxicol. 2003;22(6):465–71.CrossRefPubMedGoogle Scholar
  43. Satchell KJ. Structure and function of MARTX toxins and other large repetitive RTX proteins. Annu Rev Microbiol. 2011;65:71–90.CrossRefPubMedGoogle Scholar
  44. Schep LJ, Temple WA, Butt GA, Beasley MD. Ricin as a weapon of mass terror–separating fact from fiction. Environ Int. 2009;35(8):1267–71.CrossRefPubMedGoogle Scholar
  45. Shimada K, Ohishi K, Fukunaga H, Ro JS, Nambara T. Structure-activity relationship of bufotoxins and related compounds for the inhibition of Na+, K+-adenosine triphosphatase. J Pharmacobiodyn. 1985;8(12):1054–9.CrossRefPubMedGoogle Scholar
  46. Sudhof TC. alpha-Latrotoxin and its receptors: neurexins and CIRL/latrophilins. Annu Rev Neurosci. 2001;24:933–62.CrossRefPubMedGoogle Scholar
  47. Szinicz L. History of chemical and biological warfare agents. Toxicology. 2005;214(3):167–81.CrossRefPubMedGoogle Scholar
  48. US Code of Law. Title: 18: Crimes and criminal procedure (Part I – Crimes). Chapter 10: Biological weapons. Sect. 178: Definitions (2012).Google Scholar
  49. Wilson BA. Global biosecurity in a complex, dynamic world. Complexity. 2008;14(1):71–88.CrossRefGoogle Scholar
  50. Wilson BA, Ho M. Recent insights into Pasteurella multocida toxin and other G-protein-modulating bacterial toxins. Future Microbiol. 2010;5(8):1185–201.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Department of MicrobiologyUniversity of Illinois at Urbana-ChampaignUrbanaUSA

Personalised recommendations